Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Accounts Receivables?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2009 - 2021 (13 years)

Accounts Receivables is 
-$2.2M (1Y -100.8% )

ALXN Stock Price & Accounts Receivables

Accounts Receivables for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Accounts Receivables

chevron_right 2021 -$44.1M +0.4x *
( +2.8% / year avg)
chevron_left 2009 $30.9M
vertical_align_top Peak $318.4M +8.22x *
vertical_align_bottom Bottom -$44.1M
arrow_drop_up # Up Years 8 8 of 13
years up.
arrow_drop_down # Down Years 5
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2009 , or -18.8x faster than it's accounts receivables over the same period.
  • If ALXN grows it's stock at the same rate as it's accounts receivables (+2.8%/year) , it's stock price will grow +131% and hit $143.3 over the next 10 years.
  • ALXN's stock price has gone up 4 of the 8 years (+50%) it's accounts receivables were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Accounts Receivables Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Accounts Receivables YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $-44 -114.5% $108.72 -4.8%
    4/1/2020 $303 -4.6% $114.22 13.4%
    4/1/2019 $318 46.3% $100.76 -17.6%
    4/1/2018 $217 422.0% $122.24 -14.2%
    4/1/2017 $41 -53.7% $142.41 -5.6%
    4/1/2016 $90 -6.5% $150.9 -7.9%
    4/1/2015 $96 77.0% $163.84 -1.5%
    4/1/2014 $54 -48.7% $166.32 70.4%
    4/1/2013 $106 15.5% $97.58 7.7%
    4/1/2012 $91 32.2% $90.57 91.0%
    4/1/2011 $69 45.5% $47.42 89.6%
    4/1/2010 $47 54.5% $25.02 37.1%
    4/1/2009 $30 - $18.25 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Accounts receivables consist of the short-term obligations owed to the company by its clients. Companies often sell products or services to customers on credit; these obligations are held in the current assets account until they are paid off by the clients.

    For more detailed definitions, please see Investopedia.